Astrazeneca (AZN) Cash from Investing Activities (2009 - 2026)

Astrazeneca's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.9 billion for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 38.14% year-over-year to -$2.9 billion; the TTM figure through Jun 2026 stood at -$8.2 billion (down 34.59% YoY), while the FY2025 annual figure was -$6.8 billion, up 14.69% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at -$2.9 billion, down from -$1.8 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was -$168.0 million in Q1 2022, with the low at -$2.9 billion in Q2 2026.
• The 5-year median for Cash from Investing Activities is -$1.5 billion (2024), against an average of -$1.6 billion.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities sank 641.67% in 2023, then soared 48.07% in 2025.
• Astrazeneca's Cash from Investing Activities stood at -$800.0 million in 2022, then jumped by 35.0% to -$520.0 million in 2023, then sank by 127.12% to -$1.2 billion in 2024, then dropped by 22.44% to -$1.4 billion in 2025, then tumbled by 101.38% to -$2.9 billion in 2026.
• Business Quant data shows AZN's Cash from Investing Activities at -$2.9 billion in Q2 2026, -$1.8 billion in Q1 2026, and -$1.4 billion in Q4 2025.